Search Results
Your search for Staff matches 6663 pages
Showing 1551 - 1600Study Examines Utility, Accuracy of ChatGPT in Offering Breast Cancer Screening Recommendations
A new study suggests that the answers generated by the artificial intelligence (AI) chatbot ChatGPT may provide correct breast cancer screening advice the vast majority of the time; however, the information is sometimes inaccurate or even fictitious, according to the report published by Haver et al ...
Interferon Alfa-2b May Substantially Increase Survival in Patients With Lymphomatoid Granulomatosis
Researchers have demonstrated that patients with low-grade lymphomatoid granulomatosis who were treated with the immunotherapy interferon alfa-2b may survive for a median of 20 years after diagnosis, according to a novel study published by Melani et al in The Lancet Haematology. The findings...
Training Oncology Nurses on Primary Palliative Care May Improve End-of-Life Care and Spur Creation of Advance Directives for Patients With Cancer
Specially trained oncology infusion room nurses may be capable of improving advance care planning for patients with advanced cancer at the end of life, according to a new study published by Cohen et al in JNCCN—Journal of the National Comprehensive Cancer Network. Background “Advance care planning...
Elena Ratner, MD, MBA on Sexual Identity and Function in Cancer Survivors
Elena Ratner, MD, MBA, of Yale Cancer Center/Smilow Cancer Hospital, discusses sexuality, intimacy, fertility, and menopause as important aspects of women’s cancer survivorship and the many effects of treatment on these issues. They often go unacknowledged in the medical community, Dr. Ratner says, ...
Ella A. Kazerooni, MD, on Lung Cancer Screening: Benefits and Challenges
Ella A. Kazerooni, MD, of the University of Michigan Rogel Cancer Center, discusses reducing cancer deaths in the United States by identifying patients at risk for lung cancer. Engaging with primary care physicians and facilitating referrals are keys to a successful lung cancer screening program,...
Jordan McPherson, PharmD, MS, BCOP, on Managing Immunotherapy-Related Toxicities
Jordan McPherson, PharmD, MS, BCOP, of the Huntsman Cancer Institute at the University of Utah, summarizes a case-based panel discussion on best practices in caring for patients with immune-related adverse events. He focuses on pneumonitis, which can occur with immune checkpoint inhibitor therapy, ...
NCCN Names UChicago Medicine Comprehensive Cancer Center as 33rd Member Institution
The National Comprehensive Cancer Network (NCCN) announced that the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) has been named its newest member institution. With the addition, there are now 33 academic centers across the United States that have multidisciplinary subject...
Deductibles, Copays May Discourage Patients From Receiving Follow-up Breast Cancer Screenings
Researchers found that 20% of patients attending breast cancer screening appointments were likely to skip additional testing after abnormal findings on their mammograms if there was a deductible or copayment involved, according to a new study published by Ngo et al in Radiology. Background...
HHS Releases National Cancer Plan to Advance the Goals of the Cancer Moonshot and Improve Outcomes for All Patients
On April 3, the U.S. Department of Health and Human Services (HHS) released a National Cancer Plan, which calls for collaboration to realize the objectives laid out in the Cancer Moonshot to reduce cancer mortality by at least 50% over the next 25 years and “end cancer as we know it.” Developed by...
FDA Grants Accelerated Approval to Enfortumab Vedotin-ejfv/Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma
On April 3, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the antibody-drug conjugate enfortumab vedotin-ejfv (Padcev) in combination with the PD-1 inhibitor pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial carcinoma who are...
Deborah M. Stephens, DO, on CLL/SLL: NCCN Clinical Practice Guidelines in Oncology® Update
Deborah M. Stephens, DO, of the Huntsman Cancer Institute at the University of Utah, discusses NCCN’s updates to treatment recommendations for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Dr. Stephens details the key factors in selecting front-line and subsequent...
Mandi L. Pratt-Chapman, PhD, on Oncology Care in the LGBTQI+ Community: Best Practices for Addressing Health Needs
Mandi L. Pratt-Chapman, PhD, of the George Washington University Cancer Center, discusses the specific health-care needs for cancer screening, treatment, and survivorship among members of the LGBTQI+ community. Because clinical practices and research studies do not routinely collect sexual...
Pathologic Complete Responses May Be Prognostic of Outcomes for Patients With Soft-Tissue Sarcoma
Researchers have discovered that pathologic complete responses may be associated with improved survival outcomes for patients with localized soft-tissue sarcoma who received preoperative chemoradiotherapy or radiotherapy, according to a novel study published by Wang et al in JAMA Oncology. The new...
More U.S. Patients With Prostate Cancer May Be Electing for Active Surveillance
Since 2010, investigators have discovered that the number of patients with prostate cancer in the United States who are choosing active surveillance over surgery or radiation therapy may be rapidly increasing, according to a new study published by Al Awamlh et al in JAMA Internal Medicine....
ChatGPT May Have Potential to Help Educate Patients With Cirrhosis and Hepatic Cancer in Basic Knowledge, Lifestyle, and Treatment Domains
Investigators revealed that the artificial intelligence (AI) chatbot ChatGPT may help improve health outcomes for patients with cirrhosis and hepatic cancer by providing easy-to-understand information about basic knowledge, lifestyle modifications, and treatment options for these conditions,...
Midhun Malla, MD, on Metastatic Colorectal Cancer: Treatment Updates
Midhun Malla, MD, of the West Virginia University Cancer Institute, discusses the molecular landscape of metastatic colorectal cancer and the development and approvals of targeted treatments. Dr. Malla also details the range of HER2-targeted therapeutic options and the approval of trastuzumab and...
Louis B. Nabors, MD, on NCCN Clinical Practice Guidelines in Oncology Updates for CNS Cancers in Adults
Louis B. Nabors, MD, of the O’Neal Comprehensive Cancer Center at UAB, discusses the three subtypes of adult gliomas classified by the World Health Organization, treatments influenced by IDH mutation status, the roles of radiotherapy and chemotherapy, molecular testing, and pseudoprogression and...
Michael K. Gibson, MD, PhD, on Metastatic Esophageal Squamous Cell Carcinoma: New First-Line Systemic Treatment Options
Michael K. Gibson, MD, PhD, of Vanderbilt-Ingram Cancer Center, discusses the importance of developing additional treatment strategies for patients with advanced or metastatic esophageal squamous cell carcinoma and describes the role of immune checkpoint inhibitors. Dr. Gibson also reviews the...
ELCC 2023: New Data on Amivantamab-vmjw in Patients With Advanced NSCLC and EGFR Exon 20 Insertion Mutations
New long-term data from the CHRYSALIS study evaluating amivantamab-vmjw in patients with advanced non–small cell lung cancer (NSCLC) and EGFR exon 20 insertion mutations whose disease progressed on prior platinum-based chemotherapy were presented by Lopez et al at the 2023 European Lung Cancer...
CAR T-Cell Therapy May Improve Quality of Life of Patients With Hematologic Malignancies
Patients with hematologic malignancies may experience a significant improvement in their reported quality of life 6 months after receiving chimeric antigen receptor (CAR) T-cell therapy, according to a new study published by Johnson et al in Blood Advances. Background Although CAR T-cell therapy...
Study Assesses Prevalence, Severity, and Co-occurrence of Common Symptoms That May Be Undertreated in Patients With Cancer
Investigators have revealed the findings from an examination of the prevalence, severity, and co-occurrence of sleep disturbance, pain, physical function impairment, anxiety, depression, and low energy/fatigue (SPPADE) symptoms, as well as their association with different cancer types and patient...
Nivolumab Injected Directly Into Spinal Fluid May Be Safe and Effective for Some Patients With Melanoma Who Have Leptomeningeal Disease
Researchers have found that a novel approach to administer intrathecal and intravenous nivolumab has proven safe and improved survival in a subset of patients who developed leptomeningeal disease from metastatic melanoma, according to a new study published by Glitza Olivia et al in Nature ...
Researchers Uncover How Advanced Melanoma May Resist Treatment at the End of Life
Researchers have revealed the potential mechanisms contributing to treatment resistance in patients with melanoma at the end of life, according to a new study published by Spain et al in Cancer Discovery. “These results present the most detailed picture yet of what melanoma looks like at the final...
Clinical Trial Participation May Be Associated With Improved Overall Survival in Patients With Ovarian Cancer
Investigators have found that patients with platinum-resistant epithelial ovarian cancer who participate in clinical trials may have higher rates of overall survival compared with those who don’t participate in clinical trials, according to findings presented by Morton et al at the Society of...
Time-Related and Financial Burdens May Impact Quality of Life for Patients With Gynecologic Cancer
Time-related and financial burdens may be detrimental to the quality of life of patients with gynecologic cancer as well as cancer survivors, according to the findings from two new studies presented by Ackroyd et al and Adjei et al at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on ...
Addition of Immunotherapy to Chemotherapy Regimen May Increase Progression-Free Survival in Patients With Advanced or Recurrent Endometrial Cancer
Adding immunotherapy to standard chemotherapy may result in significantly longer progression-free survival for patients with advanced or recurrent endometrial cancer, according to the findings from two novel studies presented by Eskander et al and Mirza et al at the Society of Gynecologic Oncology...
Addition of Gemcitabine to Cisplatin and Intensity-Modulated Radiation Therapy May Improve Outcomes for Patients With Locally Advanced Vulvar Cancer
Researchers have found that concurrent treatment with gemcitabine as well as cisplatin and intensity-modulated radiation therapy may effectively increase the pathologic complete response rates in patients with locally advanced squamous cell carcinoma of the vulva, according to findings presented by ...
FDA Grants Full Approval to Pembrolizumab for Certain Adult and Pediatric Patients With Advanced MSI-H or dMMR Solid Tumors
On March 29, the U.S. Food and Drug Administration (FDA) granted full approval to the anti–PD-1 therapy pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) solid tumors, as...
Researchers Find No Significant Differences in Overall Survival Among Patients With Platinum-Sensitive Recurrent Ovarian Cancer Who Received Niraparib Maintenance Therapy vs Placebo
Researchers have found no significant differences in overall survival between patients with platinum-sensitive recurrent ovarian cancer who received maintenance therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib or placebo, according to new findings presented by Matulonis et...
Positive Outcomes Demonstrated in Patients With Ovarian Cancer Treated With Olaparib Prior to Surgical Intervention and Subsequent Chemotherapy
Treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib prior to surgical intervention and chemotherapy has demonstrated the potential for favorable surgical options, manageable adverse events, and positive health outcomes in patients with ovarian cancer who have a germline...
Atezolizumab May Be an Effective Primer for Chemoradiation in Patients With Locally Advanced Cervical Cancer
After comparing the efficacy of the anti–PD-L1 inhibitor atezolizumab prior to and concurrently with chemoradiation, researchers have indicated favorable outcomes for 2-year disease-free survival and demonstrated evidence of improved immunogenicity with neoadjuvant atezolizumab in patients with...
Brown Adipose Tissue May Not Be Associated With Cancer Cachexia, May Not Worsen Cancer Mortality
Brown adipose tissue may not be associated with cachexia, according to an article published by Eljalby et al in the American Journal of Physiology Endocrinology and Metabolism. The findings also suggested that brown adipose tissue does not increase cancer mortality. Background Brown adipose tissue...
Risk of Cervical Cancer May Be Twice as High in Patients With Mental Illnesses
Patients who have a mental illness, neuropsychiatric disability, or substance use disorder may be less likely to undergo gynecological smear tests and may have over twice the risk of developing cervical cancer, according to a new study published by Hu et al in The Lancet Public Health. The findings ...
Obesity May Contribute to Breast Cancer Risk in High-Risk Patients With BRCA Mutations
Obesity may spur DNA damage in the breast tissue of patients who carry BRCA1 or BRCA2 mutations, possibly contributing to breast cancer development in patients who are already at a higher risk of the disease, according to a new study published by Bhardwaj et al in Science Translational Medicine....
Lower-Income Patients With Early-Stage Esophageal Adenocarcinoma May Face Disparities in Cancer Care and Higher Mortality Rates
Patients with early-stage esophageal adenocarcinoma from lower-income households may be significantly less likely to receive a potentially life-saving treatment and may be more likely to die from the disease, according to a new study published by Geng et al in Clinical Gastroenterology and...
FDA Issues Draft Guidance Aimed at Improving Oncology Clinical Trials for Accelerated Approval
On March 24, the U.S. Food and Drug Administration (FDA) issued draft guidance, Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics, regarding clinical trial design considerations to support accelerated approval applications. The accelerated approval pathway is...
10 Facts About Colorectal Cancer From the Colorectal Cancer Alliance
March is widely recognized worldwide as Colorectal Cancer Awareness month. Several advocacy groups and professional organizations recognize Colorectal Cancer Awareness month by promoting screening for eligible individuals and working to increase awareness. Here, the Colorectal Cancer Alliance, an...
Studies of Novel Therapeutic Approaches Highlighted During Colorectal Cancer Awareness Month at Dana-Farber
Colorectal cancer is the third most common cancer among men and women of all ages in the United States and is on track to be the leading cause of cancer death in adults younger than 50 by 2030. The alarming rise of colorectal cancer in people younger than age 50 prompted the U.S. Preventive...
Michael Taylor, MD, PhD, Appointed Director at Texas Children’s Hospital and Baylor College of Medicine
Texas Children’s Hospital and Baylor College of Medicine recently named Michael Taylor, MD, PhD, molecular biologist and Cancer Prevention and Research Institute of Texas Scholar, as Director of the Pediatric Neuro-Oncology Research Program at Texas Children’s Hospital and Baylor College of...
Carl H. June, MD, FAACR, to Be Honored With 2023 AACR Award for Lifetime Achievement in Cancer Research
The American Associationfor Cancer Research (AACR) will award Carl H. June, MD, FAACR, Fellow of the AACR Academy, with the 2023 AACR Award for Lifetime Achievement in Cancer Research during the 2023 AACR Annual Meeting, April 14–19 in Orlando, Florida. Dr. June is the Richard W. Vague Professor in ...
Alex F. Herrera, MD, on Previously Untreated DLBCL: Circulation Tumor DNA and Risk Profiling
Alex F. Herrera, MD, of the City of Hope National Medical Center, discusses results from the POLARIX study, which showed that circulating tumor DNA (ctDNA) analysis has prognostic value for patients with previously untreated diffuse large B-cell lymphoma. Patients who did not achieve 2.5 or...
Jamie Takayesu, MD, on Genitourinary Cancer: Disparity in Physicians’ Assessment of Sexual Dysfunction in Women vs Men
Jamie Takayesu, MD, of the University of Michigan, discusses her findings on how frequently physicians are asking their female and male patients with genitourinary cancers about sexual dysfunction. Although 62.79% of women with genitourinary cancer who received brachytherapy thought they should be ...
Alex K. Bryant, MD, on PSA Screening and Metastatic Prostate Cancer in the VA Health-Care System
Alex K. Bryant, MD, of the University of Michigan, examined Veterans Administration (VA) facilities in which lower prostate-specific antigen (PSA) screening rates were associated with a subsequent increased incidence of metastatic prostate cancer, particularly among men aged 70 and older. From...
Thomas Powles, MD, PhD, and Christopher Sweeney, MBBS, on RCC: Expert Review of Two Key Studies on Atezolizumab, Nivolumab, and Ipilimumab
Thomas Powles, MD, PhD, of Barts Health NHS Trust, Queen Mary University of London, and Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, discuss two important phase III studies on renal cell cancer (RCC) presented at ESMO 2022: IMmotion010, which examined the efficacy and safety of...
Myriam Chalabi, MD, PhD, on Colon Cancer: New Findings on Neoadjuvant Immune Checkpoint Inhibition
Myriam Chalabi, MD, PhD, of The Netherlands Cancer Institute, discusses data from the NICHE-2 study, which confirms previously reported pathologic responses to short-term neoadjuvant nivolumab plus ipilimumab in patients with locally advanced mismatch repair–deficient colon cancer. Survival data...
Rahul Aggarwal, MD, on Prostate Cancer: Phase III Data on Apalutamide and Androgen Deprivation in Relapsed Disease
Rahul Aggarwal, MD, of the University of California, San Francisco, discusses recent data from the PRESTO study, which showed that apalutamide plus androgen-deprivation therapy (ADT) for 12 months significantly prolonged PSA progression-free survival compared with ADT alone in patients with...
ACCC Releases Advocacy Agenda at 49th Annual Meeting & Cancer Center Business Summit
The Association of Community Cancer Centers (ACCC) represents members nationwide from all care delivery settings. ACCC’s 49th Annual Meeting & Cancer Business Summit was held March 8–10, 2023, in Washington, DC, where the society released its advocacy agenda for 2023. Areas of Focus ACCC...
Northwell Health Names Richard D. Carvajal, MD, to Lead Medical Oncology Programs
Northwell Health has appointed Richard D. Carvajal, MD, a clinician and researcher in melanoma and early-phase drug development, as Deputy Physician-in-Chief and Director of Medical Oncology at the Northwell Health Cancer Institute. He also was named the R. J. Zuckerberg Chair in Medical Oncology....
Three MD Anderson Researchers Elected AAAS Fellows
Three researchers at The University of Texas MD Anderson Cancer Center have been named Fellows of the American Association for the Advancement of Science (AAAS) for their notable contributions to the field of cancer research. This distinction is one of the highest honors in the scientific research...
Rangaswamy Govindarajan, MD, Named Chief of UAMS Hematology and Oncology Division
The University of Arkansas for Medical Sciences (UAMS) recently announced the appointment of Rangaswamy Govindarajan, MD, as Chief of the Division of Hematology and Oncology at the UAMS Winthrop P. Rockefeller Cancer Institute. Dr. Govindarajan, who is also Professor in the division, will lead a...
